Lilly, Zepbound and weight loss
Digest more
Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per ...
Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...
Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Monday, Dec. 1, Eli Lilly announced Zepbound will cost less for those who buy the medication straight from the drugmaker.
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.
For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback